TY - STD TI - US Food and Drug Administration. Highlights of Prescribing Information - HUMIRA (adalimumab) injection, for subcutaneous use. 2011.www.rxabbvie.com/pdf/humira.pdf.Revised 1/2019. UR - http://www.rxabbvie.com/pdf/humira.pdf.Revised ID - ref1 ER - TY - STD TI - European Medicines Agency. Summary of product characteristics - Humira pre-filled pen, pre-filled syringe and vial. 2018. ID - ref2 ER - TY - JOUR AU - Schiff, M. H. AU - Burmester, G. R. AU - Kent, J. D. PY - 2006 DA - 2006// TI - Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis JO - Ann Rheum Dis VL - 65 UR - https://doi.org/10.1136/ARD.2005.043166 DO - 10.1136/ARD.2005.043166 ID - Schiff2006 ER - TY - JOUR AU - Puri, A. AU - Niewiarowski, A. AU - Arai, Y. PY - 2017 DA - 2017// TI - Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects JO - Br J Clin Pharmacol VL - 83 UR - https://doi.org/10.1111/bcp.13245 DO - 10.1111/bcp.13245 ID - Puri2017 ER - TY - JOUR AU - Lie, G. AU - Sciascia, S. AU - Cuadrado, M. J. PY - 2015 DA - 2015// TI - Biosimilar vs biological agents in rheumatology: when are biosimilar agents similar enough? JO - Int Immunopharmacol VL - 27 UR - https://doi.org/10.1016/j.intimp.2015.04.022 DO - 10.1016/j.intimp.2015.04.022 ID - Lie2015 ER - TY - JOUR AU - Isakov, L. AU - Jin, B. AU - Jacobs, I. A. PY - 2016 DA - 2016// TI - Statistical primer on biosimilar clinical development JO - Am J Ther VL - 23 UR - https://doi.org/10.1097/MJT.0000000000000391 DO - 10.1097/MJT.0000000000000391 ID - Isakov2016 ER - TY - JOUR AU - Daller, J. PY - 2016 DA - 2016// TI - Biosimilars: a consideration of the regulations in the United States and European Union JO - Regul Toxicol Pharmacol VL - 76 UR - https://doi.org/10.1016/J.YRTPH.2015.12.013 DO - 10.1016/J.YRTPH.2015.12.013 ID - Daller2016 ER - TY - STD TI - European Medicines Agency (2017) Biosimilars in the EU, Information guide for healthcare professionals. www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. UR - http://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf ID - ref8 ER - TY - STD TI - US Department of Health and Human Services, Food and Drug Administration (2015) Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Guidance for Industry. www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. UR - http://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf ID - ref9 ER -